REVIVA PHARMACEUTICALS HOLDINGS INC. - COMMON STO

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

07 يناير 2025 08:00:01 بحسب Nasdaq GlobeNewswire

Reviva Announces Pricing of $18.0 Million Public Offering of Common Stock and Warrants

16 ديسمبر 2024 22:25:45 بحسب Nasdaq GlobeNewswire

Reviva Announces Proposed Public Offering

16 ديسمبر 2024 17:18:02 بحسب Nasdaq GlobeNewswire

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

16 ديسمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

14 نوفمبر 2024 17:25:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

12 نوفمبر 2024 08:00:02 بحسب Nasdaq GlobeNewswire

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

06 نوفمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the UBS Global Healthcare Conference

31 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

08 أكتوبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

02 أكتوبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference

26 سبتمبر 2024 08:30:00 بحسب Nasdaq GlobeNewswire

Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia

09 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

04 سبتمبر 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva to Host Virtual KOL Event to Discuss Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia on September 4, 2024

27 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules

21 أغسطس 2024 06:00:00 بحسب Nasdaq GlobeNewswire

Reviva Reports Second Quarter 2024 Financial Results and Recent Business Highlights

14 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Grant of U.S. Patent Covering Use of Brilaroxazine for the Treatment of Idiopathic Pulmonary Fibrosis

06 أغسطس 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension

09 يوليو 2024 08:00:00 بحسب Nasdaq GlobeNewswire

Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

29 مايو 2024 16:45:48 بحسب Nasdaq GlobeNewswire

Reviva Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

28 مايو 2024 08:00:00 بحسب Nasdaq GlobeNewswire